Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA Members Spent $48.5 Billion On R&D In 2012

This article was originally published in The Pink Sheet Daily

Executive Summary

A report by the industry advocacy group notes that the 31 PhRMA member companies invested 20.7% of domestic sales revenue in R&D efforts last year. The aggregate total of $48.5 billion is down slightly from 2011 and a bit further from the 2010 record amount of $50.7 billion.

You may also be interested in...



QUOTED. 23 April 2021. Thomas Schinecker.

In its first quarter 2021 sales earnings report, Roche highlighted the strength of its diagnostics business as biosimilars cannibalize its pharmaceutical revenues. CEO Thomas Schinecker said the growth should continue.

US Drug Pricing Bill’s Prospects Will Be Shaped By Whether Public Worries More About Access Than Cost

HR 3 has been re-introduced, and some provisions may be attached to the White House’s infrastructure bill, but the government price negotiation system envisioned by the bill may fail – if industry can convince Congress to focus on access to medicines, not their cost.

FTC May Be Hampered In Pursuing Actions Against Pharma In Wake Of Supreme Court Ruling

High court’s decision that FTC lacks authority to seek monetary recovery in litigation is boon for drug makers who have been subject to hefty payouts in reverse settlement and other cases brought by the commission.

Topics

UsernamePublicRestriction

Register

PS075525

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel